Verification of the improvement effect of simultaneous intake of proteoglycan derived from the salmon bone cartilage, non-denatured type II collagen derived from the salmon nasal cartilage, and olive-leaf extract on the knee joint and skin quality

Verification of the improvement effect of simultaneous intake of proteoglycan derived from the salmon bone cartilage, non-denatured type II collagen derived from the salmon nasal cartilage, and olive-leaf extract on the knee joint and skin quality - Verification of the improvement effect of simultaneous intake of proteoglycan derived from the salmon bone cartilage, non-denatured type II collagen derived from the salmon nasal cartilage, and olive-leaf extract on the knee joint and skin quality

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039824

Enrollment

Registered

2020-03-23

Start date

2020-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

joint supplement intake For 12 weeks from the initiation of inoculation,Four measurement points:Day 0,Day 28, Day 56, and Day 84 placebo control intake For 12 weeks from the initiation of inoculat

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1,The age at the time of obtaining a conesent is 20 years or older 2,Female 3,Those from whom a written consent can be obtained on a voluntary basis.

Exclusion criteria

Exclusion criteria: The person who is unsuitable for the entry judged by a ficer

Design outcomes

Primary

Measure	Time frame
For 12 weeks from the initiation of inoculation,Four measurement points:Day 0,Day 28, Day 56, and Day 84 Body constituents Body compositions (body weight, body fat, volume of water, muscle mass, etc.) Skin measurement 1,Volume of water, 2,TEWL, 3,Viscoelasticity, 4,Photography Questionnaire Knee joint, feeling of effect on the skin, daily life	—

Countries

Japan

Contacts

Public ContactSaki OKUMURA

Noevir Co., Ltd. Groupwide Research and Development

saki_okumura@n1.noevir.co.jp044-813-2488

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026